2 news items
Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
ALNY
2 May 24
- $425 millionGAAP R&D and SG&A expenses
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
.
R&D Highlights
- Prev
- 1
- Next